What Is Usona Institute’s PSIL201 Psilocybin Treatment for Depression?

A second path toward prescription psilocybin

The conversation about FDA-approved psilocybin has increasingly centered on Compass Pathways and its COMP360 program. But another developer, the nonprofit Usona Institute, is pursuing psilocybin for major depressive disorder. Its research program is often identified in industry coverage by the name PSIL201, which is also the identifier of its completed Phase 2 study. Usona’s later Phase 3 trial is called PSIL301, or uAspire. These distinctions matter because readers may encounter different study names while researching the same broader development effort.

Who is Usona Institute?

Usona Institute is a nonprofit medical research organization that develops investigational treatments and supports scientific research. Its psilocybin program uses a manufactured, standardized form of the molecule found in certain mushrooms. That does not make the treatment equivalent to consuming mushrooms independently. Pharmaceutical manufacturing, controlled dosing, screening, supervision and systematic follow-up are central to the clinical research.

What condition is being studied?

Usona’s primary program targets major depressive disorder, a condition characterized by episodes of depressed mood or loss of interest accompanied by symptoms that can interfere with daily functioning. Major depressive disorder is a broader diagnosis than treatment-resistant depression, which generally describes patients who have not responded adequately to multiple antidepressant treatments. The distinction could eventually affect who qualifies for treatment, but any approved indication will depend on the FDA’s evaluation of the submitted evidence.

What do the studies involve?

Usona’s published Phase 2 research examined a single psilocybin dose in adults with major depressive disorder, with psychosocial support surrounding administration. Its Phase 3 uAspire study enrolled approximately 238 participants and compared a 25 mg dose, a 5 mg dose and an inactive placebo. The principal assessment examined changes in depressive symptoms through day 43, with longer follow-up intended to assess safety and durability. Trial registration and enrollment are not the same as published positive results, and patients should distinguish a company’s regulatory progress from independent review of complete trial findings.

What would treatment look like?

The investigational approach includes clinical assessment, preparation for an altered-state experience, a monitored dosing appointment and follow-up. A psilocybin session can occupy much of a day, and patients may experience substantial changes in perception, emotion and attention. The presence of psychosocial support in research does not establish the exact counseling requirements that would apply after approval. Those details could be determined by product labeling, safety restrictions and the delivery model adopted by qualified providers.

Where does FDA review stand?

Specialist reporting in November 2026 indicated that Usona had submitted a new drug application. Unlike Compass Pathways’ publicly announced November 9 filing, Usona’s reported submission had not been independently confirmed through a detailed company announcement at the time of writing. The FDA had previously granted the program Breakthrough Therapy designation, and Usona was reported to hold a Commissioner’s National Priority Voucher. Neither designation guarantees approval or establishes a patient-access date.

What this means for California patients

If a Usona psilocybin product is approved, patients would still need to find an appropriately equipped provider, complete screening and meet any prescribing or administration requirements. Insurance coverage, training, appointment length and controlled-substance rules could all influence access. People currently experiencing depression should continue discussing available evidence-based treatments with their clinicians rather than waiting for an investigational medication to become available.

Learn More About Psychedelic Therapy in California

Whether you’re exploring treatment options or looking for information specific to your region, continue your research with these guides.

Treatment Guides

Regional Guides

Leave A Comment

Cart
  • Your cart is empty Browse Shop
  • Get Treatment Updates

    treatment updates